{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T16:17:39Z","timestamp":1768148259058,"version":"3.49.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003356","name":"Gazi University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Gliomas have attracted attention as the most common primary tumor of the CNS. Gliomas are made up of glial components of the nervous system. They cause more than 40% of CNS neoplasms, with an increased incidence in the aged 65 years and older. Despite advances in the characterization of the pathogenesis of these tumors, gliomas remain incurable. In recent years, scientific developments have shifted the attention of scientists to the potentials of galectins in glioma biology. Many studies have reported the important functions of galectins in cancer biology, apoptosis, and escape from tumor immunity, metastasis, and angiogenesis. Although few studies in the literature evaluate galectin expressions in gliomas, in-vitro and in-vivo, no study evaluating galectin serum levels in the clinic has been reported. Therefore, within the scope of this project, the roles of GAL-1, GAL-3, and GAL-8 in glioma pathogenesis and the possible link between gliomagenesis and the serum levels of ITG\u03b2-1, HIF-1\u03b1, MMP-2, and \u2212\u20099 parameters associated with hypoxia, angiogenesis, and migration, were evaluated in newly diagnosed and untreated LGG and HGG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study included 50 HGG and 50 LGG patients and 50 healthy controls with mean ages of 55.48\u2009\u00b1\u20091.51, 41.04\u2009\u00b1\u20091.66 and 39.20\u2009\u00b1\u20091.20 years, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Serum GAL-1, -3, -8, ITG\u03b2-1, HIF-1\u03b1, MMP-2, and \u2212\u20099 levels significantly differed between the glioma and healthy control groups. In addition, serum GAL-1, -3, -8, ITG\u03b2-1, MMP-2 and \u2212\u20099 levels were significantly greater in HGG compared to LGG. Although there was no significant difference in serum HIF-1\u03b1 levels between the groups with respect to tumor grade, an increase in HGG was observed. This study is the first in the Turkish population in which serum GAL-1, -3, and \u2212\u20098 levels were clinically evaluated together in glioma pathologies with high angiogenic activity and sheds light on the role of increased serum galectin levels in the promotion of low-grade tumors to high-grade tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In this respect, we believe that GAL-8, ITG\u03b2-1, and HIF-1\u03b1 may be usable as a panel of non-invasive biomarkers for glioma diagnosis. Additionally, this study may contribute to studies on glioma treatment and the inhibition of gliomagenesis by bringing a new perspective on the targeting galectins.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-05110-0","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:37:40Z","timestamp":1749785860000},"page":"733-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical utility of GAL-8, ITG\u0392-1, and HIF-1\u03b1 as non-invasive diagnostic and prognostic biomarkers for assessing glioma"],"prefix":"10.1007","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-1213","authenticated-orcid":false,"given":"Taylan","family":"Turan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6. H.","family":"Emmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Kaymaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"G\u00f6nen\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"5110_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249. https:\/\/doi.org\/10.3322\/caac.20006","journal-title":"CA Cancer J Clin"},{"key":"5110_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"5110_CR3","doi-asserted-by":"publisher","first-page":"777962","DOI":"10.3389\/fnagi.2021.777962","volume":"13","author":"J Liu","year":"2021","unstructured":"Liu J, Li C, Wang Y, Ji P, Guo S, Zhai Y, Wang N, Lou M, Xu M, Chao M, Jiao Y, Zhao W, Feng F, Qu Y, Ge S, Wang L (2021) Prognostic and predictive factors in elderly patients with glioblastoma: A Single-Center retrospective study. Front Aging Neurosci 13:777962. https:\/\/doi.org\/10.3389\/fnagi.2021.777962","journal-title":"Front Aging Neurosci"},{"key":"5110_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00018-007-7044-8","volume":"64","author":"MT Elola","year":"2007","unstructured":"Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679\u20131700. https:\/\/doi.org\/10.1007\/s00018-007-7044-8","journal-title":"Cell Mol Life Sci"},{"key":"5110_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/oby.20016","volume":"21","author":"DH Rhodes","year":"2013","unstructured":"Rhodes DH, Pini M, Castellanos KJ, Montero-Melendez T, Cooper D, Perretti M, Fantuzzi G (2013) Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obes (Silver Spring) 21:310\u2013319. https:\/\/doi.org\/10.1002\/oby.20016","journal-title":"Obes (Silver Spring)"},{"key":"5110_CR6","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.4049\/jimmunol.173.6.3825","volume":"173","author":"A Sturm","year":"2004","unstructured":"Sturm A, Lensch M, Andre S, Kaltner H, Wiedenmann B, Rosewicz S, Dignass AU, Gabius HJ (2004) Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 173:3825\u20133837. https:\/\/doi.org\/10.4049\/jimmunol.173.6.3825","journal-title":"J Immunol"},{"key":"5110_CR7","doi-asserted-by":"publisher","first-page":"49824","DOI":"10.18632\/oncotarget.17760","volume":"8","author":"H Xue","year":"2017","unstructured":"Xue H, Liu L, Zhao Z, Zhang Z, Guan Y, Cheng H, Zhou Y, Tai G (2017) The N-terminal tail coordinates with carbohydrate recognition domain to mediate galectin-3 induced apoptosis in T cells. Oncotarget 8:49824\u201349838. https:\/\/doi.org\/10.18632\/oncotarget.17760","journal-title":"Oncotarget"},{"key":"5110_CR8","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.3171\/foc.2006.20.4.16","volume":"20","author":"RL Jensen","year":"2006","unstructured":"Jensen RL (2006) Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 20:E24. https:\/\/doi.org\/10.3171\/foc.2006.20.4.16","journal-title":"Neurosurg Focus"},{"key":"5110_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jocn.2007.06.019","volume":"14","author":"GM D\u2019Abaco","year":"2007","unstructured":"D\u2019Abaco GM, Kaye AH (2007) Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14:1041\u20131048. https:\/\/doi.org\/10.1016\/j.jocn.2007.06.019","journal-title":"J Clin Neurosci"},{"key":"5110_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673\u2013687. https:\/\/doi.org\/10.1016\/s0092-8674(02)00971-6","journal-title":"Cell"},{"key":"5110_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/med.20078","volume":"27","author":"C Decaestecker","year":"2007","unstructured":"Decaestecker C, Debeir O, Van Ham P, Kiss R (2007) Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27:149\u2013176. https:\/\/doi.org\/10.1002\/med.20078","journal-title":"Med Res Rev"},{"key":"5110_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1750-3639.2005.tb00507.x","volume":"15","author":"BN Stillman","year":"2005","unstructured":"Stillman BN, Mischel PS, Baum LG (2005) New roles for galectins in brain tumors\u2013from prognostic markers to therapeutic targets. Brain Pathol 15:124\u2013132. https:\/\/doi.org\/10.1111\/j.1750-3639.2005.tb00507.x","journal-title":"Brain Pathol"},{"key":"5110_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1750-3639.2001.tb00377.x","volume":"11","author":"I Camby","year":"2001","unstructured":"Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R (2001) Galectins are differentially expressed in supratentorial pilocytic Astrocytomas, Astrocytomas, anaplastic Astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11:12\u201326. https:\/\/doi.org\/10.1111\/j.1750-3639.2001.tb00377.x","journal-title":"Brain Pathol"},{"key":"5110_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1749-6632.1999.tb07697.x","volume":"878","author":"JF Woessner Jr","year":"1999","unstructured":"Woessner JF Jr (1999) Matrix metalloproteinase inhibition. From the jurassic to the third millennium. Ann N Y Acad Sci 878:388\u2013403. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07697.x","journal-title":"Ann N Y Acad Sci"},{"key":"5110_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1139\/o96-088","volume":"74","author":"AE Yu","year":"1996","unstructured":"Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG (1996) Molecular regulation of cellular invasion\u2013role of gelatinase A and TIMP-2. Biochem Cell Biol 74:823\u2013831. https:\/\/doi.org\/10.1139\/o96-088","journal-title":"Biochem Cell Biol"},{"key":"5110_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.pathol.1.110304.100043","volume":"1","author":"DN Louis","year":"2006","unstructured":"Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97\u2013117. https:\/\/doi.org\/10.1146\/annurev.pathol.1.110304.100043","journal-title":"Annu Rev Pathol"},{"key":"5110_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","volume":"65","author":"Y Rong","year":"2006","unstructured":"Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) Pseudopalisading\u2019 necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65:529\u2013539. https:\/\/doi.org\/10.1097\/00005072-200606000-00001","journal-title":"J Neuropathol Exp Neurol"},{"key":"5110_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1215\/S1152851704001115","volume":"7","author":"B Kaur","year":"2005","unstructured":"Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134\u2013153. https:\/\/doi.org\/10.1215\/S1152851704001115","journal-title":"Neuro Oncol"},{"key":"5110_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1750-3639.2005.tb00119.x","volume":"15","author":"JP Gagner","year":"2005","unstructured":"Gagner JP, Law M, Fischer I, Newcomb EW, Zagzag D (2005) Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol 15:342\u2013363. https:\/\/doi.org\/10.1111\/j.1750-3639.2005.tb00119.x","journal-title":"Brain Pathol"},{"key":"5110_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-024-12751-3","volume":"24","author":"R Wei","year":"2024","unstructured":"Wei R, Zhou J, Bui B, Liu X (2024) Glioma actively orchestrate a self-advantageous extracellular matrix to promote recurrence and progression. BMC Cancer 24:974. https:\/\/doi.org\/10.1186\/s12885-024-12751-3","journal-title":"BMC Cancer"},{"key":"5110_CR21","doi-asserted-by":"publisher","unstructured":"Grochans S, Cybulska AM, Siminska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I (2022) Epidemiology of glioblastoma Multiforme-Literature review. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14102412","DOI":"10.3390\/cancers14102412"},{"key":"5110_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-016-0091-6","volume":"49","author":"C Metz","year":"2016","unstructured":"Metz C, Doger R, Riquelme E, Cortes P, Holmes C, Shaughnessy R, Oyanadel C, Grabowski C, Gonzalez A, Soza A (2016) Galectin-8 promotes migration and proliferation and prevents apoptosis in U87 glioblastoma cells. Biol Res 49:33. https:\/\/doi.org\/10.1186\/s40659-016-0091-6","journal-title":"Biol Res"},{"key":"5110_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nec.2021.01.001","volume":"32","author":"O Lopes Abath Neto","year":"2021","unstructured":"Lopes Abath Neto O, Aldape K (2021) Morphologic and molecular aspects of glioblastomas. Neurosurg Clin N Am 32:149\u2013158. https:\/\/doi.org\/10.1016\/j.nec.2021.01.001","journal-title":"Neurosurg Clin N Am"},{"issue":"Suppl 2","key":"5110_CR24","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1136\/jnnp.2004.040337","volume":"75","author":"VP Collins","year":"2004","unstructured":"Collins VP (2004) Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75(Suppl 2):ii2\u201311. https:\/\/doi.org\/10.1136\/jnnp.2004.040337","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5110_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2003.11.031","volume":"30","author":"JC Buckner","year":"2003","unstructured":"Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10\u201314. https:\/\/doi.org\/10.1053\/j.seminoncol.2003.11.031","journal-title":"Semin Oncol"},{"key":"5110_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"LM DeAngelis","year":"2001","unstructured":"DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114\u2013123. https:\/\/doi.org\/10.1056\/NEJM200101113440207","journal-title":"N Engl J Med"},{"key":"5110_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5110_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1535-6108(04)00024-8","volume":"5","author":"N Rubinstein","year":"2004","unstructured":"Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted Inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241\u2013251. https:\/\/doi.org\/10.1016\/s1535-6108(04)00024-8","journal-title":"Cancer Cell"},{"key":"5110_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11060-013-1201-8","volume":"115","author":"T Verschuere","year":"2013","unstructured":"Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S (2013) Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neurooncol 115:9\u201317. https:\/\/doi.org\/10.1007\/s11060-013-1201-8","journal-title":"J Neurooncol"},{"key":"5110_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/(SICI)1097-4547(20000315)59:6-722::AID-JNR4-3.0.CO;2-H","volume":"59","author":"K Yamaoka","year":"2000","unstructured":"Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T (2000) Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 59:722\u2013730. https:\/\/doi.org\/10.1002\/(SICI)1097-4547(20000315)59:6-722::AID-JNR4-3.0.CO;2-H","journal-title":"J Neurosci Res"},{"key":"5110_CR31","doi-asserted-by":"publisher","unstructured":"Toussaint LG 3rd, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH (2012) Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol Cancer 11:32. https:\/\/doi.org\/10.1186\/1476-4598-11-32","DOI":"10.1186\/1476-4598-11-32"},{"key":"5110_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12885-018-4025-2","volume":"18","author":"SY Chou","year":"2018","unstructured":"Chou SY, Yen SL, Huang CC, Huang EY (2018) Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. BMC Cancer 18:105. https:\/\/doi.org\/10.1186\/s12885-018-4025-2","journal-title":"BMC Cancer"},{"key":"5110_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.taap.2008.01.009","volume":"229","author":"M Le Mercier","year":"2008","unstructured":"Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V (2008) Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229:172\u2013183. https:\/\/doi.org\/10.1016\/j.taap.2008.01.009","journal-title":"Toxicol Appl Pharmacol"},{"key":"5110_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","volume":"1760","author":"J Dumic","year":"2006","unstructured":"Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616\u2013635. https:\/\/doi.org\/10.1016\/j.bbagen.2005.12.020","journal-title":"Biochim Biophys Acta"},{"key":"5110_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/glycob\/cwy001","volume":"28","author":"P Nangia-Makker","year":"2018","unstructured":"Nangia-Makker P, Hogan V, Raz A (2018) Galectin-3 and cancer stemness. Glycobiology 28:172\u2013181. https:\/\/doi.org\/10.1093\/glycob\/cwy001","journal-title":"Glycobiology"},{"key":"5110_CR36","doi-asserted-by":"publisher","first-page":"744518","DOI":"10.3389\/fmed.2021.744518","volume":"8","author":"Y An","year":"2021","unstructured":"An Y, Xu S, Liu Y, Xu X, Philips CA, Chen J, Mendez-Sanchez N, Guo X, Qi X (2021) Role of galectins in the liver diseases: A systematic review and Meta-Analysis. Front Med (Lausanne) 8:744518. https:\/\/doi.org\/10.3389\/fmed.2021.744518","journal-title":"Front Med (Lausanne)"},{"key":"5110_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.36401\/JIPO-24-6","volume":"7","author":"S Chamseddine","year":"2024","unstructured":"Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO (2024) Circulating Galectin-3: A prognostic biomarker in hepatocellular carcinoma. J Immunother Precis Oncol 7:255\u2013262. https:\/\/doi.org\/10.36401\/JIPO-24-6","journal-title":"J Immunother Precis Oncol"},{"key":"5110_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.12659\/MSM.892386","volume":"21","author":"D Cheng","year":"2015","unstructured":"Cheng D, Liang B, Li Y (2015) Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit 21:755\u2013760. https:\/\/doi.org\/10.12659\/MSM.892386","journal-title":"Med Sci Monit"},{"key":"5110_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3892\/br.2016.696","volume":"5","author":"T Shimura","year":"2016","unstructured":"Shimura T, Shibata M, Gonda K, Nakajima T, Chida S, Noda M, Suzuki S, Nakamura I, Ohki S, Takenoshita S (2016) Association between Circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer. Biomed Rep 5:203\u2013207. https:\/\/doi.org\/10.3892\/br.2016.696","journal-title":"Biomed Rep"},{"key":"5110_CR40","doi-asserted-by":"publisher","first-page":"11583","DOI":"10.1111\/jcmm.15775","volume":"24","author":"N Yi","year":"2020","unstructured":"Yi N, Zhao X, Ji J, Xu M, Jiao Y, Qian T, Zhu S, Jiang F, Chen J, Xiao M (2020) Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. J Cell Mol Med 24:11583\u201311591. https:\/\/doi.org\/10.1111\/jcmm.15775","journal-title":"J Cell Mol Med"},{"key":"5110_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1055-9965.EPI-18-0638","volume":"28","author":"H Wang","year":"2019","unstructured":"Wang H, Song X, Huang Q, Xu T, Yun D, Wang Y, Hu L, Yan Y, Chen H, Lu D, Chen J (2019) LGALS3 promotes treatment resistance in glioblastoma and is associated with tumor risk and prognosis. Cancer Epidemiol Biomarkers Prev 28:760\u2013769. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0638","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5110_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fmed.2020.00182","volume":"7","author":"WM Hu","year":"2020","unstructured":"Hu WM, Yang YZ, Zhang TZ, Qin CF, Li XN (2020) LGALS3 is a poor prognostic factor in diffusely infiltrating gliomas and is closely correlated with CD163\u2009+\u2009Tumor-Associated macrophages. Front Med (Lausanne) 7:182. https:\/\/doi.org\/10.3389\/fmed.2020.00182","journal-title":"Front Med (Lausanne)"},{"key":"5110_CR43","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cam4.2075","volume":"8","author":"X He","year":"2019","unstructured":"He X, Zhang S, Chen J, Li D (2019) Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma. Cancer Med 8:2031\u20132040. https:\/\/doi.org\/10.1002\/cam4.2075","journal-title":"Cancer Med"},{"key":"5110_CR44","doi-asserted-by":"publisher","first-page":"e111592","DOI":"10.1371\/journal.pone.0111592","volume":"9","author":"RY Ikemori","year":"2014","unstructured":"Ikemori RY, Machado CM, Furuzawa KM, Nonogaki S, Osinaga E, Umezawa K, de Carvalho MA, Verinaud L, Chammas R (2014) Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival. PLoS ONE 9:e111592. https:\/\/doi.org\/10.1371\/journal.pone.0111592","journal-title":"PLoS ONE"},{"key":"5110_CR45","doi-asserted-by":"publisher","unstructured":"Ajarrag S, St-Pierre Y (2021) Galectins in glioma: current roles in Cancer progression and future directions for improving treatment. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13215533","DOI":"10.3390\/cancers13215533"},{"key":"5110_CR46","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","volume":"17","author":"H Barrow","year":"2011","unstructured":"Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM, Yu LG (2011) Serum galectin-2, -4, and\u2013\u20098 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17:7035\u20137046. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1462","journal-title":"Clin Cancer Res"},{"key":"5110_CR47","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00404-022-06449-9","volume":"306","author":"S Beyer","year":"2022","unstructured":"Beyer S, Wehrmann M, Meister S, Kolben TM, Trillsch F, Burges A, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Kolben T (2022) Galectin-8 and\u2013\u20099 as prognostic factors for cervical cancer. Arch Gynecol Obstet 306:1211\u20131220. https:\/\/doi.org\/10.1007\/s00404-022-06449-9","journal-title":"Arch Gynecol Obstet"},{"key":"5110_CR48","doi-asserted-by":"publisher","unstructured":"Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NBB, Wells M, Staudinger C, Griswold A, Chandler KB, Marrero C, Jimenez R, Tani Y, Wilmott JS, Thompson JF, Wang W, Sackstein R, Scolyer RA, Murphy GF, Haslam SM, Dimitroff CJ (2023) Hypoxia Controls the Glycome Signature and Galectin-8-Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma. J Invest Dermatol 143: 456\u2013469 e458 https:\/\/doi.org\/10.1016\/j.jid.2022.07.033","DOI":"10.1016\/j.jid.2022.07.033"},{"key":"5110_CR49","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbamcr.2019.03.010","volume":"1866","author":"F Ferragut","year":"2019","unstructured":"Ferragut F, Cagnoni AJ, Colombo LL, Sanchez Terrero C, Wolfenstein-Todel C, Troncoso MF, Vanzulli SI, Rabinovich GA, Marino KV, Elola MT (2019) Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM\/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta Mol Cell Res 1866:1338\u20131352. https:\/\/doi.org\/10.1016\/j.bbamcr.2019.03.010","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"5110_CR50","doi-asserted-by":"publisher","first-page":"44654","DOI":"10.18632\/oncotarget.17963","volume":"8","author":"LD Gentilini","year":"2017","unstructured":"Gentilini LD, Jaworski FM, Tiraboschi C, Perez IG, Kotler ML, Chauchereau A, Laderach DJ, Compagno D (2017) Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer. Oncotarget 8:44654\u201344668. https:\/\/doi.org\/10.18632\/oncotarget.17963","journal-title":"Oncotarget"},{"key":"5110_CR51","doi-asserted-by":"publisher","first-page":"13244","DOI":"10.1038\/s41598-017-13802-5","volume":"7","author":"M Labrie","year":"2017","unstructured":"Labrie M, De Araujo LOF, Communal L, Mes-Masson AM, St-Pierre Y (2017) Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep 7:13244. https:\/\/doi.org\/10.1038\/s41598-017-13802-5","journal-title":"Sci Rep"},{"key":"5110_CR52","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/gut.50.3.392","volume":"50","author":"N Nagy","year":"2002","unstructured":"Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R, Gabius HJ (2002) Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50:392\u2013401. https:\/\/doi.org\/10.1136\/gut.50.3.392","journal-title":"Gut"},{"key":"5110_CR53","doi-asserted-by":"publisher","first-page":"834307","DOI":"10.3389\/fonc.2022.834307","volume":"12","author":"H Zhu","year":"2022","unstructured":"Zhu H, Liu D, Cheng L, Liu J, Wang G, Li H, Zhang Y, Mi H, Zhang S, Shu K, Yu X (2022) Prognostic value and biological function of galectins in malignant glioma. Front Oncol 12:834307. https:\/\/doi.org\/10.3389\/fonc.2022.834307","journal-title":"Front Oncol"},{"key":"5110_CR54","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/neuonc\/noad264","volume":"26","author":"D Liu","year":"2024","unstructured":"Liu D, Zhu H, Cheng L, Li R, Ma X, Wang J, Wang J, Zhang S, Li Y, Shu K, Yu X, Li C (2024) Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation. Neuro Oncol 26:872\u2013888. https:\/\/doi.org\/10.1093\/neuonc\/noad264","journal-title":"Neuro Oncol"},{"key":"5110_CR55","first-page":"1021","volume":"32","author":"P Bartik","year":"2008","unstructured":"Bartik P, Maglott A, Entlicher G, Vestweber D, Takeda K, Martin S, Dontenwill M (2008) Detection of a hypersialylated beta1 integrin endogenously expressed in the human Astrocytoma cell line A172. Int J Oncol 32:1021\u20131031","journal-title":"Int J Oncol"},{"key":"5110_CR56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J (2018) Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 18:533\u2013548. https:\/\/doi.org\/10.1038\/s41568-018-0038-z","journal-title":"Nat Rev Cancer"},{"key":"5110_CR57","first-page":"154","volume":"143","author":"W Paulus","year":"1993","unstructured":"Paulus W, Baur I, Schuppan D, Roggendorf W (1993) Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 143:154\u2013163","journal-title":"Am J Pathol"},{"key":"5110_CR58","doi-asserted-by":"publisher","first-page":"14612","DOI":"10.1038\/s41598-019-51108-w","volume":"9","author":"A Saleh","year":"2019","unstructured":"Saleh A, Marhuenda E, Fabre C, Hassani Z, Weille J, Boukhaddaoui H, Guelfi S, Maldonado IL, Hugnot JP, Duffau H, Bauchet L, Cornu D, Bakalara N (2019) A novel 3D nanofibre scaffold conserves the plasticity of glioblastoma stem cell invasion by regulating galectin-3 and integrin-beta1 expression. Sci Rep 9:14612. https:\/\/doi.org\/10.1038\/s41598-019-51108-w","journal-title":"Sci Rep"},{"key":"5110_CR59","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/neuonc\/not046","volume":"15","author":"M Petras","year":"2013","unstructured":"Petras M, Lajtos T, Friedlander E, Klekner A, Pintye E, Feuerstein BG, Szollosi J, Vereb G (2013) Molecular interactions of ErbB1 (EGFR) and integrin-beta1 in Astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol 15:1027\u20131040. https:\/\/doi.org\/10.1093\/neuonc\/not046","journal-title":"Neuro Oncol"},{"key":"5110_CR60","doi-asserted-by":"publisher","unstructured":"Min W, Zou C, Dai D, Zuo Q, Chen C, Xu J, Li Y, Yue Z (2020) Integrin Beta 1 Promotes Glioma Cell Proliferation by Negatively Regulating the Notch Pathway. J Oncol 2020: 8297017 https:\/\/doi.org\/10.1155\/2020\/8297017","DOI":"10.1155\/2020\/8297017"},{"key":"5110_CR61","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12967-023-04696-1","volume":"21","author":"L Sun","year":"2023","unstructured":"Sun L, Guo S, Xie Y, Yao Y (2023) The characteristics and the multiple functions of integrin beta1 in human cancers. J Transl Med 21:787. https:\/\/doi.org\/10.1186\/s12967-023-04696-1","journal-title":"J Transl Med"},{"key":"5110_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1631\/jzus.B1400221","volume":"16","author":"ZJ Liu","year":"2015","unstructured":"Liu ZJ, Semenza GL, Zhang HF (2015) Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B 16:32\u201343. https:\/\/doi.org\/10.1631\/jzus.B1400221","journal-title":"J Zhejiang Univ Sci B"},{"key":"5110_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xing C, Deng Y, Ye C, Peng H (2024) HIF-1alpha signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis 11:234\u2013251. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.039","journal-title":"Genes Dis"},{"key":"5110_CR64","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3892\/or.2016.5309","volume":"37","author":"G Wang","year":"2017","unstructured":"Wang G, Wang JJ, Fu XL, Guang R, To ST (2017) Advances in the targeting of HIF-1alpha and future therapeutic strategies for glioblastoma multiforme (Review). Oncol Rep 37:657\u2013670. https:\/\/doi.org\/10.3892\/or.2016.5309","journal-title":"Oncol Rep"},{"key":"5110_CR65","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W","volume":"88","author":"D Zagzag","year":"2000","unstructured":"Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606\u20132618","journal-title":"Cancer"},{"key":"5110_CR66","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.18632\/oncotarget.6582","volume":"7","author":"MA Sharpe","year":"2016","unstructured":"Sharpe MA, Baskin DS (2016) Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1alpha and with transcription factors Sp1 and Sp3. Oncotarget 7:3379\u20133393. https:\/\/doi.org\/10.18632\/oncotarget.6582","journal-title":"Oncotarget"},{"key":"5110_CR67","doi-asserted-by":"publisher","first-page":"102731","DOI":"10.1016\/j.amsu.2021.102731","volume":"69","author":"F Sfifou","year":"2021","unstructured":"Sfifou F, Hakkou EM, Bouaiti EA, Slaoui M, Errihani H, Al Bouzidi A, Abouqal R, El Ouahabi A, Cherradi N (2021) Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of Moroccan glioblastoma and survival analysis. Ann Med Surg (Lond) 69:102731. https:\/\/doi.org\/10.1016\/j.amsu.2021.102731","journal-title":"Ann Med Surg (Lond)"},{"key":"5110_CR68","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s12031-022-02065-z","volume":"72","author":"SA El-Benhawy","year":"2022","unstructured":"El-Benhawy SA, Sakr OA, Fahmy EI, Ali RA, Hussein MS, Nassar EM, Salem SM, Abu-Samra N, Elzawawy S (2022) Assessment of serum hypoxia biomarkers Pre- and Post-radiotherapy in patients with brain tumors. J Mol Neurosci 72:2303\u20132312. https:\/\/doi.org\/10.1007\/s12031-022-02065-z","journal-title":"J Mol Neurosci"},{"key":"5110_CR69","doi-asserted-by":"publisher","first-page":"12694","DOI":"10.1038\/s41598-023-39914-9","volume":"13","author":"DS Dzhalilova","year":"2023","unstructured":"Dzhalilova DS, Zolotova NA, Mkhitarov VA, Kosyreva AM, Tsvetkov IS, Khalansky AS, Alekseeva AI, Fatkhudinov TH, Makarova OV (2023) Morphological and molecular-biological features of glioblastoma progression in tolerant and susceptible to hypoxia Wistar rats. Sci Rep 13:12694. https:\/\/doi.org\/10.1038\/s41598-023-39914-9","journal-title":"Sci Rep"},{"key":"5110_CR70","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00207454.2013.789874","volume":"123","author":"J Reszec","year":"2013","unstructured":"Reszec J, Rutkowski R, Chyczewski L (2013) The expression of hypoxia-inducible factor-1 in primary brain tumors. Int J Neurosci 123:657\u2013662. https:\/\/doi.org\/10.3109\/00207454.2013.789874","journal-title":"Int J Neurosci"},{"key":"5110_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02482169","volume":"21","author":"N Irie","year":"2004","unstructured":"Irie N, Matsuo T, Nagata I (2004) Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 21:1\u20136. https:\/\/doi.org\/10.1007\/BF02482169","journal-title":"Brain Tumor Pathol"},{"key":"5110_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1515\/oncologie-2023-0004","volume":"25","author":"YH Lin","year":"2023","unstructured":"Lin YH, Wu ZY (2023) Hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1)-activated Gli1 induces invasion and EMT by H3K4 methylation in glioma cells. Oncologie 25:71\u201379. https:\/\/doi.org\/10.1515\/oncologie-2023-0004","journal-title":"Oncologie"},{"key":"5110_CR73","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1183\/09031936.94.07112062","volume":"7","author":"JM Ray","year":"1994","unstructured":"Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062\u20132072","journal-title":"Eur Respir J"},{"key":"5110_CR74","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1089\/neu.1995.12.833","volume":"12","author":"GA Rosenberg","year":"1995","unstructured":"Rosenberg GA (1995) Matrix metalloproteinases in brain injury. J Neurotrauma 12:833\u2013842. https:\/\/doi.org\/10.1089\/neu.1995.12.833","journal-title":"J Neurotrauma"},{"key":"5110_CR75","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/sj.bjc.6690291","volume":"79","author":"PA Forsyth","year":"1999","unstructured":"Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79:1828\u20131835. https:\/\/doi.org\/10.1038\/sj.bjc.6690291","journal-title":"Br J Cancer"},{"key":"5110_CR76","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s0002-9440(10)62308-5","volume":"166","author":"P Guo","year":"2005","unstructured":"Guo P, Imanishi Y, Cackowski FC, Jarzynka MJ, Tao HQ, Nishikawa R, Hirose T, Hu B, Cheng SY (2005) Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 166:877\u2013890. https:\/\/doi.org\/10.1016\/s0002-9440(10)62308-5","journal-title":"Am J Pathol"},{"key":"5110_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF00157684","volume":"14","author":"RE Sawaya","year":"1996","unstructured":"Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS (1996) Expression and localization of 72\u00a0kda type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14:35\u201342. https:\/\/doi.org\/10.1007\/BF00157684","journal-title":"Clin Exp Metastasis"},{"key":"5110_CR78","first-page":"3010","volume":"11","author":"R Sinceviciute","year":"2018","unstructured":"Sinceviciute R, Vaitkiene P, Urbanaviciute R, Steponaitis G, Tamasauskas A, Skiriute D (2018) MMP2 is associated with glioma malignancy and patient outcome. Int J Clin Exp Pathol 11:3010\u20133018","journal-title":"Int J Clin Exp Pathol"},{"key":"5110_CR79","doi-asserted-by":"publisher","unstructured":"Urbanaviciute R, Skauminas K, Skiriute D (2020) The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients\u2019 Diagnosis and Prognosis. Brain Sci 10. https:\/\/doi.org\/10.3390\/brainsci10110872","DOI":"10.3390\/brainsci10110872"},{"key":"5110_CR80","doi-asserted-by":"publisher","first-page":"e0172234","DOI":"10.1371\/journal.pone.0172234","volume":"12","author":"RK Ramachandran","year":"2017","unstructured":"Ramachandran RK, Sorensen MD, Aaberg-Jessen C, Hermansen SK, Kristensen BW (2017) Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in Astrocytomas. PLoS ONE 12:e0172234. https:\/\/doi.org\/10.1371\/journal.pone.0172234","journal-title":"PLoS ONE"},{"key":"5110_CR81","first-page":"1","volume":"7","author":"JG Shehan","year":"2019","unstructured":"Shehan JG, Vengoji S, Rachagani R, Zhang S, Mallya Y, Pai K, Kaur P, Jain S, Kueh M, White A, Aizenberg M, McComb M, Smith RD, Cohen L, Batra MZ, S.K.; and, Shonka N (2019) MMP-2 AND NGAL AS BIOMARKERS IN GLIOBLASTOMA: A PILOT STUDY. Med Res Archives 7:1\u201317","journal-title":"Med Res Archives"},{"key":"5110_CR82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jcu.23402","volume":"51","author":"W Liu","year":"2023","unstructured":"Liu W, Li Z (2023) Diagnostic performance of perfusion-weighted imaging combined with serum MMP-2 and\u2013\u20099 levels in tumor recurrence after postoperative concomitant chemoradiotherapy of glioblastoma. J Clin Ultrasound 51:563\u2013570. https:\/\/doi.org\/10.1002\/jcu.23402","journal-title":"J Clin Ultrasound"},{"key":"5110_CR83","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/ol.2017.5567","volume":"13","author":"Q Xue","year":"2017","unstructured":"Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li SZ, Fei Z (2017) High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett 13:1325\u20131330. https:\/\/doi.org\/10.3892\/ol.2017.5567","journal-title":"Oncol Lett"},{"key":"5110_CR84","doi-asserted-by":"publisher","first-page":"109369","DOI":"10.1016\/j.biopha.2019.109369","volume":"118","author":"W Zhou","year":"2019","unstructured":"Zhou W, Yu X, Sun S, Zhang X, Yang W, Zhang J, Zhang X, Jiang Z (2019) Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence. Biomed Pharmacother 118:109369. https:\/\/doi.org\/10.1016\/j.biopha.2019.109369","journal-title":"Biomed Pharmacother"},{"key":"5110_CR85","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11060-011-0628-z","volume":"105","author":"FM Iwamoto","year":"2011","unstructured":"Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A (2011) Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 105:607\u2013612. https:\/\/doi.org\/10.1007\/s11060-011-0628-z","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05110-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:16:11Z","timestamp":1757186171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05110-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05110-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Research Ethics Committee of Gazi University with the decision number 2021-15\/558 dated 23.06.2021. All procedures involving people comply with the ethical standards of the institutional and\/or national committee for research ethics and the 1964 Helsinki Declaration and its subsequent changes or comparable ethical standards. Informed written consent was achieved from all the subjects included in the study according to the ethical standards of the Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The research is financed by the Gazi University Scientific Research Projects Unit with project number TGA-2021-7296.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}